- Home
- IQI vs PCRX Comparison
IQI vs PCRX Comparison
Compare IQI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQI | PCRX |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.8M | 1.0B |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IQI | PCRX |
|---|---|---|
| Price | $9.47 | $23.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.60 |
| AVG Volume (30 Days) | 118.0K | ★ 796.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $7.10 |
| Revenue Next Year | N/A | $9.15 |
| P/E Ratio | ★ N/A | $146.94 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $8.86 | $18.80 |
| 52 Week High | $10.42 | $27.99 |
Technical Indicators
Market Signals| Indicator | IQI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 20.42 | 57.50 |
| Support Level | $9.27 | $22.57 |
| Resistance Level | $9.48 | $23.91 |
| Average True Range (ATR) | 0.11 | 0.91 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 4.67 | 80.61 |
Price Performance
Historical ComparisonAbout IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.